- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00985634
Clinical Evaluation of LeGoo™ Internal Vessel Occluder Versus Traditional Vessel Loops (LeGoo)
Randomized Clinical Evaluation of LeGoo™ Internal Vessel Occluder Vs Traditional Vessel Loops
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to evaluate the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. LeGoo is a device that is intended to be used during surgical procedures to temporarily occlude blood vessels while forming an anastomosis. LeGoo™ will be evaluated in subjects undergoing off-pump coronary artery by-pass (OPCAB) surgery. This is a prospective, randomized trial with a 30-day follow-up period. Half of the eligible patients will be randomized to the experimental group (LeGoo™); and the other half to the control group (standard vessel loops).
LeGoo™ is polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a "plug" form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer can never re-solidify.
The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.
Satisfactory hemostasis is defined by the surgeon who will quantitate his/her observation about the quality of the surgical field using the following scoring system:
- - Excellent hemostasis (no bleeding)
- - Minimal bleeding (bleeding does not interfere with suturing)
- - Modest bleeding (required intermittent use of another device to control bleeding at the site of the anastomosis)
- - Copious bleeding (required continuous use of another device)
"Excellent hemostasis" and "minimal bleeding" are considered "satisfactory hemostasis." Satisfactory hemostasis will constitute a treatment success for the purpose of evaluating the primary efficacy of LeGoo. The primary endpoint is the proportion of anastomoses in which satisfactory hemostasis is achieved.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: James A Wilkie, BS
- Phone Number: 781 932 0574
- Email: jwilkie@pluromed.com
Study Contact Backup
- Name: Jean-Marie Vogel, BS
- Phone Number: 781 932 0574
- Email: jvogel@pluromed.com
Study Locations
-
-
-
Leipzig, Germany
- Recruiting
- Klinik fur Herzchirurgie Herzzentrum Leipzig
-
Contact:
- Ardawan Rastan, MD
- Phone Number: 49 341 865-1421
- Email: jwilkie@pluromed.com
-
Principal Investigator:
- Ardawan Rastan, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects undergoing elective off pump coronary artery bypass (OPCAB) surgery where the surgeon prospectively plans to use a vascular occlusion device.
- >70% proximal stenosis of at least one target coronary artery, other than left main
- Age: between the ages 18 -79 years
- Gender: male and female
- Subject is willing and able to participate in a clinical research study and provides informed consent.
- Subject is able and willing to participate in required follow-up procedures.
Exclusion Criteria:
- Previous cardiac surgery.
- Left ventricular dysfunction (EF <40%)
- >50% of left main coronary artery stenosis
- Subjects with a logistic EuroScore equal to or greater than 10% as calculated by the euroscore.org calculator
- Emergent Surgery: Subjects undergoing surgery before the start of the next working day following catheterization
- Creatinine > 200 µmol/L
- Bilirubin > 21 µmol/L
- Subjects with chronic pulmonary disease [ FEV1 < 45% ]
- Any subject who is deemed by the investigator, for any reason, not suitable or able to participate in a clinical research study.
- Pregnant women. Women of childbearing age will require a pregnancy test within 10 days of the operation and will be excluded if the result is positive.
- Women who are lactating.
- Subjects who have undergone other investigational therapy within 30 days prior to the operation or who are scheduled to receive investigational therapy within six months of the operation.
- Subjects suspected to have one intra-myocardial artery among the coronary arteries to be bypassed during that surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LeGoo
Subjects in this arm, which is assigned at random, will receive the study device.
|
LeGoo internal vessel occluder.
Usage (dose) as required and determined by surgeon.
|
Active Comparator: Control
Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
|
Vessel loops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary research hypothesis is that surgeons will obtain a bloodless surgical field and achieve satisfactory hemostasis in a larger proportion of anastomoses using LeGoo™ than using a conventional temporary hemostasis technique.
Time Frame: in operating room
|
in operating room
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total duration of the anastomosis, blood loss during the surgery, Time required to occlude the vessel, the number of units of blood transfused during hospitalization.
Time Frame: in operating room (day of surgery)
|
in operating room (day of surgery)
|
Safety will be measured by comparing a composite of four serious adverse events experienced by the treated and control groups: death, graft occlusion, myocardial damage, and low post procedure cardiac output.
Time Frame: one month post op
|
one month post op
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- LeGoo EURO rev D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Off Pump Coronary Artery Bypass Surgery
-
Peking University Third HospitalNot yet recruitingCoronary Artery Bypass, Off-PumpChina
-
Peking University Third HospitalRecruitingCoronary Artery Bypass, Off-PumpChina
-
General Hospital of Ningxia Medical UniversityUnknownCoronary Artery Bypass, Off-PumpChina
-
University Medical Center GroningenTerminated
-
Chinese Academy of Medical Sciences, Fuwai HospitalCompletedOff Pump Coronary Artery Bypass SurgeryChina
-
University Hospital, GhentCAS Medical Systems, Inc.; Belgian Foundation for Cardiac SurgeryCompletedElective Off-pump Coronary Artery Bypass GraftingBelgium
-
Assiut UniversityUnknownAcute Normovolemic Hemodilution | Off-Pump Coronary Artery Bypass SurgeryEgypt
-
Yonsei UniversityCompletedOff Pump Coronary Artery Bypass SurgeryKorea, Republic of
-
Samsung Medical CenterCompletedOff Pump Coronary Artery Bypass GraftKorea, Republic of
-
University Hospital DubravaCompletedCoronary Artery Disease | Off Pump Coronary Artery Bypass SurgeryCroatia